Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Eplerenone, a new selective aldosterone blocker.

Ellen G McMahon1

  • 1Mail Zone T1G, Pharmacia Corporation, 800 North Lindbergh Blvd., St. Louis, Missouri 63167, USA. ellen.g.mcmahon@pharmacia.com

Current Pharmaceutical Design
|April 8, 2003
PubMed
Summary

New research shows that aldosterone, even when not blocked by common drugs, drives cardiovascular damage. The selective aldosterone blocker eplerenone demonstrates protective effects, offering potential benefits for hypertension and heart failure patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone.

Mini reviews in medicinal chemistry·2005
Same author

Emerging therapies for heart failure.

Expert opinion on emerging drugs·2005
Same author

The evolution of aldosterone antagonists.

Molecular and cellular endocrinology·2004
Same author

Aldosterone target organ protection by eplerenone.

Molecular and cellular endocrinology·2004
Same author

Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure.

Circulation research·2003
Same author

Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats.

Kidney international·2003

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Pharmacology

Background:

  • Activation of the renin-angiotensin-aldosterone system is linked to poor outcomes in hypertension and heart failure, contributing to end-organ damage.
  • Despite treatments like ACE inhibitors and ARBs, elevated aldosterone remains a significant cardiovascular disease risk factor.
  • Emerging preclinical evidence indicates aldosterone exerts detrimental cardiovascular effects beyond its known renal actions.

Purpose of the Study:

  • To evaluate the cardiovascular and renal protective effects of the selective aldosterone blocker eplerenone.
  • To assess the potential therapeutic benefits of eplerenone in hypertension and heart failure post-myocardial infarction.

Main Methods:

  • Preclinical studies investigating the effects of aldosterone on cardiovascular systems.

Related Experiment Videos

  • Experimental models of cardiovascular disease to assess eplerenone's efficacy.
  • Early clinical trials in patients with hypertension and heart failure post-myocardial infarction.

    • Main Results:

    • Eplerenone demonstrated significant cardioprotective and renoprotective effects in experimental cardiovascular disease models.
    • Preclinical data supports aldosterone's independent deleterious cardiovascular effects.
    • Early clinical studies suggest therapeutic potential for eplerenone.

    Conclusions:

    • Selective aldosterone blockade with eplerenone shows promise in mitigating cardiovascular damage.
    • Eplerenone may offer therapeutic advantages in managing hypertension and heart failure, particularly post-myocardial infarction.
    • Targeting aldosterone offers a novel strategy for cardiovascular disease treatment.